Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide, Decitabine, and Anti-PD-1 in R/R cHL
NCT06563778Phase 2Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Sep 2024
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat, decitabine in classical Hodgkin lymphoma (cHL), sponsored by Chinese PLA General Hospital. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
tucidinostatdecitabine
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT06563778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06563778.